LFMD LIFEMD INC

LifeMD Announces Continued and Rapid Expansion of Virtual Primary Care To over 200 Conditions

LifeMD Announces Continued and Rapid Expansion of Virtual Primary Care To over 200 Conditions

LifeMD’s Virtual Primary Care platform now addresses over 200 conditions with its robust infrastructure of doctors, medical professionals, pharmacies, and lab testing capabilities.

NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: LFMD, a leading direct-to-patient telehealth company, today announced the continued and rapid expansion of its Virtual Primary Care platform.

Since its launch, LifeMD’s patient-first, virtual primary care platform has continued to expand its ‘active’ treatment offerings, where patients can now access the platform to address over 200 of the most common medical conditions, ranging from migraines to arthritis, and most recently, COVID.

“We consider our Virtual Primary Care platform as one of the most exciting aspects of LifeMD, both in terms of growth potential and the impact it could have on American healthcare,” said LifeMD CEO Justin Schreiber. “The rapid growth of this platform reflects our maturation from a product-oriented telehealth company, into a full-spectrum telehealth provider.”

“One of our biggest, recent growth areas is addressing COVID-positive patients that can benefit from FDA-approved or authorized treatments, such as Paxlovid,” added LifeMD CEO Justin Schreiber. “Using our platform to help patients access potentially life-saving treatment, including prescription medications and lab tests, goes to the core of LifeMD’s mission: build an accessible telehealth business with a robust platform capable of treating hundreds of conditions at an affordable price. We’re only beginning to see the potential of telehealth, and we are very excited about the future of LifeMD’s Virtual Primary Care offering.

About LifeMD

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging our proprietary technology platform, affiliated 50-state medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Company Contact

LifeMD, Inc.

Marc Benathen, CFO



Investor Relations Contact

Ashley Robinson

LifeSci Advisors, LLC

 



EN
19/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE

LifeMD Reports Fourth Quarter and Full Year 2025 Results

LifeMD Reports Fourth Quarter and Full Year 2025 Results Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels.Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth.Benefits infrastructure on track to cover approximately 220 million America...

 PRESS RELEASE

LifeMD to Participate in Two Investor Conferences During March

LifeMD to Participate in Two Investor Conferences During March NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. ...

 PRESS RELEASE

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9 NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archiv...

 PRESS RELEASE

LifeMD Announces Closing of $50 Million Revolving Credit Facility with...

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A. NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was dra...

 PRESS RELEASE

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealt...

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end teleh...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch